Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;79(7):1952-1961.
doi: 10.1111/all.16089. Epub 2024 Mar 4.

Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination

Affiliations

Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination

Anika M Valk et al. Allergy. 2024 Jul.

Abstract

Background: The noninflammatory immunoglobulin G4 (IgG4) is linked to tolerance and is unique to humans. Although poorly understood, prolonged antigenic stimulation and IL-4-signaling along the T helper 2-axis may be instrumental in IgG4 class switching. Recently, repeated SARS-CoV-2 mRNA vaccination has been linked to IgG4 skewing. Although widely used immunosuppressive drugs have been shown to only moderately affect humoral responses to SARS-CoV-2 mRNA vaccination, the effect on IgG4 switching has not been investigated.

Methods: Here we study the impact of such immunosuppressive drugs, including the IL-4 receptor-blocking antibody dupilumab, on IgG4 skewing upon repeated SARS-CoV-2 mRNA vaccination. Receptor-binding domain (RBD) specific antibody responses were longitudinally measured in 600 individuals, including patients with immune-mediated inflammatory diseases treated with a TNF inhibitor (TNFi) and/or methotrexate (MTX), dupilumab, and healthy/untreated controls, after repeated mRNA vaccination.

Results: We observed a substantial increase in the proportion of RBD-specific IgG4 antibodies (median 21%) in healthy/untreated controls after third vaccination. This IgG4 skewing was profoundly reduced in dupilumab-treated patients (<1%). Unexpectedly, an equally strong suppression of IgG4 skewing was observed in TNFi-treated patients (<1%), whereas MTX caused a modest reduction (7%). RBD-specific total IgG levels were hardly affected by these immunosuppressive drugs. Minimal skewing was observed, when primary vaccination was adenoviral vector-based.

Conclusions: Our results imply a critical role for IL-4/IL-13 as well as TNF in vivo IgG4 class switching. These novel findings advance our understanding of IgG4 class switch dynamics, and may benefit humoral tolerance induction strategies, treatment of IgG4 pathologies and mRNA vaccine optimization.

Keywords: IgG4 class switching; TNFi; dupilumab; mRNA vaccination; tolerance.

PubMed Disclaimer

References

REFERENCES

    1. Rispens T, Huijbers MG. The unique properties of IgG4 and its roles in health and disease. Nat Immunol. 2023;1–16:763‐778. doi:10.1038/s41577-023-00871-z
    1. Lighaam LC, Rispens T. The immunobiology of immunoglobulin G4. Semin Liver Dis. 2016;36:200‐215.
    1. Labrijn AF, Rispens T, Meesters J, et al. Species‐specific determinants in the IgG CH3 domain enable fab‐arm exchange by affecting the noncovalent CH3–CH3 interaction strength. J Immunol. 2011;187:3238‐3246.
    1. Rispens T, Davies AM, Ooijevaar‐de Heer P, et al. Dynamics of inter‐heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic fab arm exchange. J Biol Chem. 2014;289:6098‐6109.
    1. Aalberse RC, Schuurman J, Van Ree R. The apparent monovalency of human IgG4 is due to bispecificity. Int Arch Allergy Immunol. 1999;118:187‐189.

Publication types

MeSH terms

LinkOut - more resources